



**Vaccines and Global Health: The Week in Review**  
**05 April 2025 :: Issue 793**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

*:: [Think Tanks](#)*

*:: [Public Consultations/Call for Inputs/Call for Papers](#)*

## ***Milestones, Perspectives***

.....  
.....

### **Pandemic Response**

#### **WHO brings countries together to test collective pandemic response**

4 April 2025 News release

Over the past two days, WHO convened more than 15 countries and over 20 regional health agencies, health emergency networks and other partners to test, for the first time, a new global coordination mechanism for health emergencies.

**The two-day simulation, Exercise Polaris, tested WHO's Global Health Emergency Corps (GHEC), a framework designed to strengthen countries' emergency workforce, coordinate the deployment of surge teams and experts, and enhance collaboration between countries. The exercise simulated an outbreak of a fictional virus spreading across the world.**

**Participating countries included** Canada, Colombia, Costa Rica, Denmark, Ethiopia, Germany, Iraq, Kingdom of Saudi Arabia, Mozambique, Nepal, Pakistan, Qatar, Somalia Uganda and Ukraine, with additional countries as observers. Each country participated through its national health emergency coordination structure and worked under real-life conditions to share information, align policies and activate their response.

**Regional and global health agencies and organizations, including Africa CDC, European CDC, IFRC, IOM, UNICEF and established emergency networks** such as the Global Outbreak Alert and Response Network, the Emergency Medical Teams initiative, Stand-by partners and the International Association of National Public Health Institutes, worked together to support country-led responses. More than 350 health emergency experts connected globally through this exercise.

"This exercise proves that when countries lead and partners connect, the world is better prepared," **said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. "No country can face the next pandemic alone. Exercise Polaris shows that global cooperation is not only possible – it is essential."**

Throughout the simulation, countries led their own response efforts while engaging with WHO for coordination, technical guidance and emergency support. **The exercise provided a rare opportunity for governments to test preparedness in a realistic environment, one where trust and mutual accountability were as critical as speed and capacity...**

#### ***Editor's Note:***

Unhappily, we noticed that the U.S. is not listed among the countries participating, and the CDC [U.S.] was not listed among the regional and global health agencies and organizations participating in this exercise.

.....  
.....

### **Pandemic Response**

#### **How to stop the next pandemic: ECDC publishes guidance to strengthen public health preparedness in the EU/EEA**

2 Apr 2025

The European Centre for Disease Prevention and Control (ECDC) has published a set of recommendations for preparedness planning for public health threats, offering tailored guidance for **improving readiness for future health emergencies across European Union/European Economic Area (EU/EEA) countries, at both national and regional levels...**

*From lessons learned to actionable recommendations*

ECDC identified several thematic lessons from recent crises, including the need for sustained investment in public health, strong governance and leadership with a defined role for the public health sector, cross-sectoral collaboration, equitable access to care, and improved risk communication. **These are translated into specific recommendations for each phase of the ECDC model of the preparedness cycle:**

**:: Anticipation:** Countries are encouraged to conduct cross-sectoral risk mapping, scenario-based planning, and capacity assessments. Tools such as the [Joint External Evaluation \(JEE\)](#) and [States Parties Self-Assessment Annual Reporting \(SPAR\)](#) can support these efforts.

**:: Response:** Establishing national coordination structures, maintaining public health emergency operation centres, deploying real-time analytics, and developing clear escalation protocols are recommended, as well as digital surveillance systems and platforms such as EpiPulse.

**:: Recovery:** After-Action Reviews (AARs) and In-Action Reviews (IARs), with a focus on health system restoration, adaption of existing plans, workforce support, and rebuilding public trust are important for the constant evaluation of the preparedness cycle.

*A strong focus on communication*

The guidance has a strong focus on risk communication, community engagement, and infodemic management (RCCE-IM). Countries are advised to form multidisciplinary RCCE-IM teams and engage proactively with communities, particularly when implementing public health and social measure.

*The priority for workforce readiness*

Recommendations include developing surge capacity strategies, supporting healthcare staff's wellbeing, and investing in recruitment, training, and retention – particularly of the staff working in public health and the management of infectious disease outbreaks.

*Tools, country lessons, and technical resources*

The guidance features a range of case studies during and after a public health crisis from several EU/EEA countries, the European Commission and ECDC, and includes a catalogue of resources from ECDC, WHO and other international organisations to assist public health planners.

.....

**[Recommendations for preparedness planning for public health threats](#)**

EU/EEA :: Public health guidance 2 Apr 2025

*Executive summary*

This document, together with the [ECDC recommendations on the implementation of public health and social measures \(PHSMs\)](#) for health emergencies and pandemics published in 2024, form a package of concrete recommendations for preparedness planning for the EU/EEA countries.

Lessons learned primarily from the response to the COVID-19 pandemic, but also from the response to the multicountry mpox outbreak in 2022–23, were collected through various activities from Member States, the European Commission, the World Health Organization (WHO) and the WHO Regional Office from Europe. We have then presented these in the form of specific recommendations for planners within each phase of the continuous cycle of preparedness (Anticipation, Response and Recovery),

following a prototype structure of a preparedness and response plan. In each section, we have presented a relevant example from a Member State or international organisation to illustrate their practice or attempt to implement lessons after COVID-19 or the mpox outbreak. These examples were identified either through literature review or communication with representatives of the countries within ECDC's network for Preparedness and Response.

Annex 1 includes an overview of the main lessons for the public health sector and Annex 2 includes a compiled catalogue of documents, tools and other resources for public health preparedness planning.

.....  
.....

## **Vaccine Clinical Trials Capacity – Africa**

### **Boosting advanced-stage clinical trial capacity in East and Central Africa to combat regional epidemic threats**

:: **The CEPI-backed Research Preparedness Program in East and Central Africa** aims to bolster regional clinical trial capacity and disease outbreak readiness.

:: The partnership will support regional stakeholders to **strengthen clinical research capacity to conduct late-stage clinical trials for vaccines against endemic and epidemic threats**; and to rapidly generate evidence in case of a new disease outbreak, in support of the 100 Days Mission.

31 March 2025; OSLO; SEATTLE: **CEPI has selected PATH—an international nonprofit global health organization—to be the Technical Coordinating Partner to initially lead the Research Preparedness Program in East and Central Africa (RPECA Program)**, which aims to bolster local clinical trial capacity and disease outbreak readiness. Having high-quality clinical trial and research capacity at the ready in outbreak-prone areas, so that vaccine trials can begin within weeks of a new outbreak, has been identified as a crucial enabler of the 100 Days Mission—a global goal, spearheaded by CEPI and embraced by the G7 and G20, to deliver pandemic vaccines in just 100 days

**Supported with up to US\$3.5 million from CEPI, the RPECA Program will expand existing regional capabilities to conduct high-quality, multi-country, late-stage clinical trials to evaluate the efficacy of vaccines against regional epidemic threats**, such as Rift Valley fever and mpox. With this established research infrastructure, the RPECA Program will also support long-term outbreak preparedness by helping to prepare sustainable clinical research centers that can rapidly generate vaccine evidence against future epidemic threats.

"PATH's extensive research and capacity development experience in this part of Africa makes them a well-suited partner for the Research Preparedness Program in East and Central Africa," said Kent Kester, Executive Director of R&D at CEPI. "Leveraging their existing capabilities will provide a strong foundation to further engage local partners to expand advanced-stage clinical trial capability and research preparedness in the region. So, when future outbreaks emerge in the area, high-quality emergency data for vaccines can be rapidly generated, and outbreaks ended sooner."

**PATH, as a Technical Coordinating Partner, will work with a consortium of regional stakeholders to identify and strengthen the capacity of clinical research sites across East and Central Africa.** Leveraging existing regional clinical research capacity and expertise, this initiative ultimately seeks to establish additional Good Clinical Practice-compliant late-stage clinical trial facilities capable of conducting the crucial research needed to advance and license vaccines against endemic and epidemic threats. Conducting these advanced-stage trials is a prerequisite for regulatory approval of a vaccine and can only take place in countries where such viruses are circulating.

**"PATH is honored to partner with CEPI on meeting this critical need for facilitating advanced clinical trial readiness in East and Central Africa," said Jessica Milman, Global Head of the Center for Vaccine Innovation and Access at PATH.** "We look forward to working with country partners and applying our decades of experience as both a scientific leader and research partner in designing and implementing clinical trials worldwide to establish the infrastructure needed to adequately prepare the region to rapidly respond to future disease outbreaks."

.....  
.....

## Featured Journal Content

### Science

Volume 388| Issue 6742| 4 Apr 2025

<https://www.science.org/toc/science/current>

*Policy Forum*

### **Rubella and measles: The beginning of the endgame**

BY Matthew J. Ferrari, William J. Moss

03 Apr 2025: 32-34

*Benchmarks must be established and progress tracked to set a global target and take action*  
*[Excerpts]*

A September 2024 recommendation from the World Health Organization (WHO) for universal introduction of rubella-containing vaccines (RCVs) into childhood vaccination programs in all countries paves the way to dramatically reduce, and ultimately eradicate, congenital rubella syndrome (CRS), which affects tens of thousands of families each year ([1](#)). It removes a critical barrier to the introduction of rubella vaccination in most of the remaining 19 countries yet to do so. Because rubella vaccine is delivered in combination with measles vaccine and introduction will involve large campaigns to vaccinate all children under 15 years of age, this recommendation provides an opportunity to move much closer to the ultimate goal: a world without measles or rubella. With planning for this goal currently paused, the programmatic, operational, and research communities must come together to establish empirical benchmarks that countries have progressed far enough for a global target to be set and the "endgame" to begin...

... Last, the role of the Pan American Health Organization (PAHO) as an exemplar, partner, and beneficiary of rubella and measles elimination planning cannot be overstated. PAHO's success with regional elimination of both measles and rubella viruses serves as an inspiration for success elsewhere ([14](#)). There is enthusiasm for measles and rubella elimination across the other global regions, and these regions will benefit from the experience of PAHO's success ([15](#)). The risk of reestablishment of rubella and measles virus transmission in the Western Hemisphere as a result of waning support for vaccination, US withdrawal from the WHO, and recent US threats to eliminate international health funding looms as a dark cloud on the horizon that could undermine the potential for a monumental human achievement. Civil society organizations such as the American Red Cross and Lions Clubs International, which played an outsized role in support for measles elimination in the United States, need to unite to ensure continued vigilance and support for rubella and measles elimination at the highest levels of national governments.

RCV introduction through wide-age-range campaigns will result in a massive, hopefully coordinated increase in population immunity against both rubella and measles viruses in many countries at greatest risk of outbreaks. Imperfect routine vaccination systems mean that this population immunity will rapidly begin to erode upon the completion of the last campaign. Despite disagreement among partners about the timing and feasibility of an eradication agenda for either rubella or measles, a short-term investment now would bring Africa an order of magnitude closer to achieving measles and rubella

elimination, lead to a major global reduction in deaths and disability from measles and CRS, reduce the risk (and cost) of outbreaks and the reestablishment of transmission in eliminated countries, and at least leave the door open for capitalizing on the high population immunity that will result from RCV introduction. If we wait to further garner support and develop plans for eradication until after scaling up vaccination against rubella, we will be racing against the clock to make decisions and plans before it is too late and the opportunity has passed. We are in the rare position of knowing that the conditions for eradication will improve, even before we have decided to take it. If we wait until 2030 to have this discussion about the endgame, we will lose ground and miss this distinct opportunity.

.....  
.....

## Yellow Fever

### [PAHO issues new epidemiological alert amid rising yellow fever cases in the Americas](#)

Washington, D.C., March 31, 2025 (PAHO) – The Pan American Health Organization (PAHO) has issued a new epidemiological alert in response to an increase in yellow fever cases across the Americas during the first months of 2025. **The number of confirmed human cases as of March 22 has more than doubled compared to the total recorded in all of 2024, raising concerns about a potential expansion of the disease.**

In the first almost three months of 2025, 131 human cases have been confirmed, with 53 deaths. In comparison, 61 cases were reported throughout 2024, 30 of which were fatal. The cases are located in Bolivia (1 case, 1 death), Brazil (81 cases, 31 deaths), Colombia (31 cases, 13 deaths), and Peru (18 cases, 8 deaths), with cases reported beyond the traditionally affected Amazon region.

Particularly concerning are the new cases reported since October 2024 in the department of Tolima, Colombia, which indicates the virus is appearing in areas not previously affected in past years. In these regions, activities such as agriculture represent a risk factor for exposure to the virus. **The increase in cases and their geographic spread highlights the urgent need to strengthen surveillance, prevention, and control measures to contain the disease.**

In addition, the epidemiological situation in the state of São Paulo, Brazil, with 34 cases and 19 deaths, is worrying due to its proximity to densely populated urban centers, increasing the risk of a larger outbreak...

Yellow fever is a serious viral disease transmitted by mosquitoes, which can be fatal but is preventable through vaccination. The vast majority of the cases detected have involved individuals who were not vaccinated.

**In an alert issued on March 27, PAHO calls for intensifying vaccination efforts in at-risk areas, aiming for coverage rates above 95%.** Vaccination is the most effective tool to combat the disease.

**PAHO also recommends that countries review their vaccine stocks, ensure rapid response plans for outbreaks, and make sure travelers to endemic areas are informed and vaccinated...**

.....  
.....

## Polio – PHEIC

## **Polio this week – 02 April 2025**

### **Headlines**

*No new digest content identified.*

### **Summary of new polioviruses this week, cases and positive environmental isolates:**

- Pakistan: 19 WPV1-positive environmental samples
- Algeria: two cVDPV2-positive environmental samples
- Chad: two cVDPV2 cases and one cVDPV2-positive environmental sample
- Nigeria: two cVDPV2-positive environmental samples
- Senegal: one cVDPV2-positive environmental sample

.....  
.....

### **mPox – PHEIC**

*No new digest content identified.*

.....  
.....

### **Contents [click to move among sections]**

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

### **WHO & Regional Offices [to 05 Apr 2025]**

<https://www.who.int/news>

*Selected News/Announcements/Statements*

4 April 2025 *News release*

### **WHO brings countries together to test collective pandemic response**

1 April 2025 *News release*

### **WHO issues its first-ever reports on tests and treatments for fungal infections**

31 March 2025 *Medical product alert*

### **WHO information notice for users of malaria IVDs 2025/1**

.....

### **WHO Regional Offices**

*Selected Press Releases, Announcements*

### **WHO African Region AFRO**

:: 04 April 2025

### **Côte d'Ivoire: self-testing extends cervical cancer screening services**

:: 02 April 2025

### **Uganda launches largest malaria vaccine introduction to date**

## **WHO Region of the Americas PAHO**

:: 2 Apr 2025

### **[As the humanitarian crisis continues, PAHO sends almost three tons of essential medicines and health supplies to Haiti](#)**

Port-au-Prince, Haiti, 2 April 2025, (PAHO/WHO) - As part of its commitment to address the prolonged humanitarian crisis in Haiti, the Pan American Health Organization (PAHO/WHO) sent a new shipment of almost three tons of essential medicines and health supplies from its Strategic Reserve in Panama, which arrived in the country today. The shipment...

:: 31 Mar 2025

### **[PAHO issues new epidemiological alert amid rising yellow fever cases in the Americas](#)**

Washington, D.C., March 31, 2025 (PAHO) – The Pan American Health Organization (PAHO) has issued a new epidemiological alert in response to an increase in yellow fever cases across the Americas during the first months of 2025. The number of confirmed human cases as of March 22 has more than doubled compared to the total recorded in all of 2024,...

## **WHO South-East Asia Region SEARO**

:: 4 April 2025 *News release*

### **[WHO scales up emergency response in earthquake-hit Myanmar, provides 100 tons of medicines and supplies, coordination of Emergency Medical Teams on the ground](#)**

## **WHO European Region EURO**

:: 4 April 2025 *News release*

### **[EU-funded water stations sustain health services for over a million people in Kharkiv region, Ukraine](#)**

## **WHO Eastern Mediterranean Region EMRO**

:: **[Fatima: crossing deserts to protect mothers and newborns in Pakistan](#)**

3 April 2025

:: **[Improving health care for Afghan refugees and host communities in Pakistan](#)**

2 April 2025

## **WHO Western Pacific Region**

*No new digest content identified.*

.....

## **WHO - Emergency situation reports**

*Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.*

*No new digest content identified.*

.....

## **Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

*No new digest content identified.*

.....

## **Weekly Epidemiological Record**

Vol. 100, Nos. 13/14, pp. 103–122 28 March 2025

<https://www.who.int/publications/journals/weekly-epidemiological-record>

*Reviewed earlier.*

.....

## **New WHO Publications**

<https://www.who.int/publications>

*Selected*

2 April 2025

**[Antimicrobial resistance prevention and education in schools: a brief for education policy-makers and...](#)**

1 April 2025

**[Report of the fifth meeting of the Technical Advisory Group on NCD-related Research and Innovation](#)**

1 April 2025

**[Landscape analysis of commercially available and pipeline in vitro diagnostics for fungal priority pathogens](#)**

1 April 2025

**[Antifungal agents in clinical and preclinical development: overview and analysis](#)**

.....

.....

## **USA – HHS, FDA, CDC+**

### ***Editor's Note:***

*We employ bolded red text below to identify observations we assess might be useful to readers.*

## **HHS**

*News*

**[HHS, ED, and GSA Initiate Federal Contract and Grant Review of Harvard University](#)**

March 31, 2025 *Press Release*

*Measures include a comprehensive review of federal contracts and grants as part of an investigation aimed at eliminating anti-Semitic harassment on college campuses*

**NIH** [to 05 Apr 2025]

<http://www.nih.gov/>

*News Releases*

Tuesday, April 1, 2025

**[Jay Bhattacharya Begins Tenure as 18th Director of the National Institutes of Health](#)**

## **FDA**

*Press Announcements*

**[April 1, 2025 - Martin A. Makary, M.D., M.P.H., Sworn in as FDA Commissioner](#)**

Renowned surgeon-scientist and health policy expert, Martin A. Makary, M.D., M.P.H., took the oath of office to become the 27th Commissioner of Food and Drugs. Dr. Makary was confirmed by a bipartisan vote of the U.S. Senate...

## **FDA VRBPAC**

### Advisory Committee Calendar

***The Advisory Committee calendar does not list any future scheduled meetings of VRBPAC. One other advisory committee meeting has been added to the overall calendar in the last week.***

### **CDC/ACIP [U.S.]** [to 05 Apr 2025]

<http://www.cdc.gov/media/index.html>

#### *Latest News*

*No new digest content identified. Last media release on Feb 27, 2025]*

### **ACIP Meetings** [to 05 Apr 2025]

#### *Next ACIP Meetings*

:: April 15-16

[Draft ACIP April 15-16, 2025 Meeting Agenda \(posted 3-24-2025\)](#)

[Previous ACIP Feb. 26-28, 2025 Meeting Agenda \(rescheduled, posted 1-17-2025\)](#)

:: June 25-26

:: October 22-23

### **National Vaccine Program**

<https://www.hhs.gov/vaccines/about/index.html>

#### *Upcoming Meetings/Latest Updates*

***No 2025 meeting dates posted.***

### **MMWR Weekly**

<https://www.cdc.gov/mmwr/index2025.html>

#### **April 3, 2025 / No. 11**

##### [PDF of this issue](#)

- [Human Metapneumovirus Seasonality and Co-Circulation with Respiratory Syncytial Virus — United States, 2014–2024](#)
- [Epidemiology of Symptomatic Human Metapneumovirus Infection in the CASCADIA Community-Based Cohort — Oregon and Washington, 2022–2024](#)
- [Notes from the Field: Response to a Case of Travel-Associated Lassa Fever — Iowa, October–November 2024](#)

.....

.....

### **Europe**

#### **European Centre for Disease Prevention and Control**

<https://www.ecdc.europa.eu/en>

*News/Updates/Reports/Publications [Selected]*

#### *News*

**[How to stop the next pandemic: ECDC publishes guidance to strengthen public health preparedness in the EU/EEA](#)**

2 Apr 2025

#### *Surveillance and monitoring*

**[Communicable disease threats report, 29 March - 4 April 2025, week 14](#)**

4 Apr 2025

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 29 March - 4 April 2025 and includes updates on SARS-CoV-2, Influenza A(H5N1), chikungunya, Ebola and an overview of respiratory virus epidemiology in the EU/EEA.

#### *Surveillance and monitoring*

### **[A scoping review and survey on Evidence-to-Decision Frameworks in public health](#)**

4 Apr 2025

The aim of this scoping review is to identify existing Evidence-to-Decisions frameworks, the criteria used by the frameworks to guide decision-making, and highlight experiences with those frameworks.

#### **European Medicines Agency [EMA]**

<https://www.ema.europa.eu/en/news>

#### *News & Press Releases*

### **[Clinical Trials Information System designated as WHO primary registry](#)**

Designation facilitates data sharing, promotes transparency and trust in clinical research  
3 April 2025

### **[EU recommendations for 2025/2026 seasonal flu vaccine composition](#)**

Yearly updates to virus strains ensure vaccine effectiveness  
1 April 2025

### **[Streamlining development and assessment of biosimilar medicines](#)**

Proposal aims to encourage development and improve patient access  
1 April 2025

### **[First report on EU-wide sales and use of antimicrobials in animals](#)**

Data comes from EU27 plus Iceland and Norway  
31 March 2025

.....  
.....

#### **Africa CDC** [to 05 Apr 2025]

<https://africacdc.org/>

#### *Press Releases, Statements [Selected]*

#### *Manuals, Guidelines & Frameworks*

### **[Africa's Health Financing in a New Era – April, 2025](#)**

*Concept Paper* April 2025

*Download the Concept Paper here: [Africa's Health Financing in a New Era – April, 2025 – Africa CDC](#)*

#### *Annual Report*

### **[Annual Report: 2024 A Year of Innovation, Response, and Resilience](#)**

3 April 2025

#### *Press Releases*

### **[Continued Partnership to Enhance Pathogen Genomic Surveillance and Bioinformatics for Public Health in Africa](#)**

Addis Ababa, Ethiopia, March 31, 2025 — In a strategic move to bolster Africa's preparedness for future pandemics, the Africa Centres for Disease Control and Prevention (Africa CDC), in partnership with the African Society for Laboratory Medicine (ASLM) and with support from the Mastercard Foundation, has launched a groundbreaking program on genomic surveillance and bioinformatics to enhance public health resilience across the continent.

The program, launched under Phase II of the Saving Lives and Livelihoods (SLL) initiative, aims to strengthen Africa's ability to respond effectively to pandemic preparedness and response by building robust infrastructure in molecular diagnostics, genomic sequencing, biobanking, and bioinformatics across African Union (AU) Member States....

.....

### **China CDC+**

<http://www.chinacdc.cn/en/>

### **National Health Commission of the People's Republic of China** [to 05 Apr 2025]

<http://en.nhc.gov.cn/>

*News*

*No new digest content identified.*

### **National Medical Products Administration – PRC** [to 05 Apr 2025]

<http://english.nmpa.gov.cn/>

*News*

*No new digest content identified.*

### **China CDC**

#### **CCDC Weekly Reports: Current Volume (7)**

**2025-04-04 / No. 14**

[PDF of this issue](#)

- [Perspectives: World Health Day 2025: Time to Change Mindset Beyond Global Commitment to Maternal Health and Women's Well-Being](#)
- [Methods and Applications: A Novel Matching Pursuit Modeling Strategy Based on Adaptive Fourier Decomposition Theory for Predicting Antigenic Variation of Influenza A \(H1N1\)](#)
- [Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, February 2025](#)

.....

.....

### ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....

.....

### ***Organization Announcements***

### **Paul G. Allen Frontiers Group** [to 05 Apr 2025]

<https://alleninstitute.org/news-press/>

*News*

*No new digest content identified.*

**BMGF - Gates Foundation** [to 05 Apr 2025]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases & Statements*

*No new digest content identified.*

**Bill & Melinda Gates Medical Research Institute** [to 05 Apr 2025]

<https://www.gatesmri.org/news>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*News: Articles and Publications*

*No new digest content identified.*

**CARB-X** [to 05 Apr 2025]

<https://carb-x.org/>

*News*

04.02.2025 |

**[CARB-X funds ArrePath to advance novel antibiotic to treat multidrug-resistant infections](#)**

CARB-X will award \$3.7 million to ArrePath to execute a Lead Optimization workplan for its first-in-class antibiotic targeting a clinically novel target for the treatment of complicated urinary tract infections caused by multidrug-resistant (MDR) Enterobacterales.

**Chan Zuckerberg Initiative** [to 05 Apr 2025]

<https://chanzuckerberg.com/newsroom/>

*Newsroom*

*No new digest content identified.*

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 05 Apr 2025]

<http://cepi.net/>

*CEPI News, Blog*

*News*

**[Pioneering vaccine tech could pave the way for all-in-one shots against rapidly mutating viruses](#)**

The \$5 million project led by Centivax could help validate the potential to use the technology against strains influenza, COVID-19 and HIV.

1 Apr 2025

*News*

**[Boosting advanced-stage clinical trial capacity in East and Central Africa to combat regional epidemic threats](#)**

30 Mar 2025

The CEPI-backed Research Preparedness Program in East and Central Africa aims to bolster regional clinical trial capacity and disease outbreak readiness.

The partnership will support regional stakeholders to strengthen clinical research capacity to conduct late-stage clinical trials for vaccines against endemic and epidemic threats; and to rapidly generate evidence in case of a new disease outbreak, in support of the 100 Days Mission...

News

**AI-enhanced self-amplifying mRNA vaccine set to combat one of the deadliest known viruses**

30 Mar 2025

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 05 Apr 2025]

<https://cioms.ch/>

News; Publications; Events

No new digest content identified.

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 05 Apr 2025]

<https://www.darpa.mil/news>

News

No new digest content identified.

**DNDI – Drugs for Neglected Diseases initiative** [to 05 Apr 2025]

<https://dndi.org/press/press-releases/>

Press Releases

No new digest content identified.

**Duke Global Health Innovation Center** [to 05 Apr 2025]

<https://dukeghic.org/>

News

**Issue 11: 3 April 2025 | Mpox Transparency and Accountability for the Global Response**

April 3, 2025

... In the wake of the U.S. health agencies' communications and foreign aid freezes, we hope to serve as a resource for transparency on emerging outbreaks globally while continuing to provide in-depth analysis of the mpox response. We will provide brief updates on emerging outbreaks with the state of available medical countermeasures and diagnostics needed to effectively respond...

**EDCTP** [to 05 Apr 2025]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

No new digest content identified.

**Emory Vaccine Center** [to 05 Apr 2025]

<http://www.vaccines.emory.edu/>

Vaccine Center News

No new digest content identified.

**European Vaccine Initiative** [to 05 Apr 2025]

<http://www.euvaccine.eu/>  
*Latest News, Events*  
*No new digest content identified.*

**Fondation Merieux** [to 05 Apr 2025]  
<http://www.fondation-merieux.org/>  
*News, Events*  
*Événement co-organisé par la Fondation Mérieux & l'Université de Genève*  
**25ème Cours avancé de vaccinologie (ADVAC)**  
5-16 mai 2025 - Centre des Pensières, Veyrier-du-Lac (France)

**Gavi** [to 05 Apr 2025]  
<https://www.gavi.org/>  
*Press Releases*  
4 April 2025  
**Gavi-funded meningococcal vaccines arrive in Nigeria to aid outbreak response**  
Kebbi, 4 April 2025 – This week, Nigeria’s Ministry of Health received over 1,000,000 pentavalent meningococcal conjugate vaccine (Men5CV) doses from the Gavi-funded global stockpile to combat the meningococcus C and W outbreak in northern Nigeria. The outbreak has already claimed over 70 lives, with more than 800 cases across 23 states...

2 April 2025  
**Uganda launches largest malaria vaccine introduction to date**

**GE2P2 Global Foundation** [to 05 Apr 2025]  
[www.ge2p2.org](http://www.ge2p2.org)  
*News/Analysis/Publications-Digests/Statements*  
:: [Vaccines and Global Health: The Week in Review](#) - Current edition  
:: [Informed Consent: A Monthly Review – April 2025](#)  
:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 20 Mar 2025](#)  
:: [Genomics :: Governance, Ethics, Policy, Practice – A Monthly Digest – March 2025](#)

**GHIT Fund** [to 05 Apr 2025]  
<https://www.ghitfund.org/newsroom/press>  
*Press Releases*  
*No new digest content identified.*

**Global Fund** [to 05 Apr 2025]  
<https://www.theglobalfund.org/en/news/>  
*News Releases*  
02 April 2025  
**Global Fund Secures First Eighth Replenishment Pledge – A Historic Private Sector Commitment from Children’s Investment Fund Foundation**  
The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) today announced the first pledge to its Eighth Replenishment Campaign – and it comes from the private sector. The Children’s Investment Fund Foundation (CIFF) has made a ground...

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 05 Apr 2025]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified.*

**Hilleman Laboratories** [to 05 Apr 2025]

<http://www.hilleman-labs.org/>

*News & Insights*

*No new digest content identified.*

**HHMI - Howard Hughes Medical Institute** [to 05 Apr 2025]

<https://www.hhmi.org/news>

*Press Room*

*No new digest content identified.*

**Human Immunome Project [nee Human Vaccines Project]** [to 05 Apr 2025]

<https://www.humanimmunomeproject.org/>

*News*

*Website not responding at inquiry.*

**IAVI** [to 05 Apr 2025]

<https://www.iavi.org/>

*Press Releases, Features*

*Features*

**[IAVI and Japan's premier global health organization pilot Human Resource Development Program](#)**

April 1, 2025

Visiting scientist Taka Funaki learned about IAVI's discovery, regulatory, manufacturing, and clinical trial expertise in the program's first two-week exchange.

**INSERM** [to 05 Apr 2025]

<https://www.inserm.fr/en/home/>

*Press Releases*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use]** [to 05 Apr 2025]

<https://www.ich.org/>

*News/Pubs/Press Releases [Selective]*  
*No new digest content identified.*

**IFRC** [to 05 Apr 2025]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press release 04/04/2025*

**[One Week On: IFRC Scales Up Myanmar Earthquake Response Amid Massive Humanitarian Needs](#)**

**IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

**IFRC** [to 05 Apr 2025]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press release 04/04/2025*

**[One Week On: IFRC Scales Up Myanmar Earthquake Response Amid Massive Humanitarian Needs](#)**

**IPPS - International Pandemic Preparedness Secretariat** [to 05 Apr 2025]

<https://ippsecretariat.org/news/>

*News*

*No new digest content identified.*

**Institut Pasteur** [to 05 Apr 2025]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*Press release 31.03.2025*

**[MOPEVACLAS vaccine candidate for Lassa fever enters clinical trials](#)**

After more than 20 years of research on arenaviruses, an Institut Pasteur team led by Sylvain Baize has developed an...

**ISC / International Science Council** [to 05 Apr 2025]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*Latest Updates*

*No new digest content identified.*

**International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News/Events [Selected]*

**[19th International Congress of Immunology](#)**

Vienna, August 17-22, 2025.

**IVAC** [to 05 Apr 2025]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

**IVI** [to 05 Apr 2025]

<http://www.ivi.int/>

*IVI News & Announcements*

[\*\*Kerstin Westritschnig joins International Vaccine Institute as Head of its Austria office\*\*](#)

**Johns Hopkins Center for Health Security** [to 05 Apr 2025]

<https://centerforhealthsecurity.org/newsroom>

*Center News [Selected]*

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 05 Apr 2025]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Colombia*

[\*\*Worsening conflict leaves tens of thousands without essential care in Colombia\*\*](#)

Press Release 2 Apr 2025

*Gaza-Israel war*

[\*\*One month into deadly Israeli-imposed blockade, critical medicines in Gaza start to run out\*\*](#)

Press Release 2 Apr 2025

*Mali*

[\*\*MSF resumes medical activities in central Mali\*\*](#)

Interview 1 Apr 2025

*Cholera*

[\*\*People affected by violence and cholera in South Sudan arrive exhausted in Ethiopia\*\*](#)

Press Release 31 Mar 2025

**National Academy of Medicine** - USA [to 05 Apr 2025]

<https://nam.edu/programs/>

*News [Selected]*

*No new digest content identified.*

**National Academies-Sciences-Engineering-Medicine [NASEM]**- USA [to 05 Apr 2025]

<https://www.nationalacademies.org/newsroom>

*News*

*No new digest content identified.*

**PATH** [to 05 Apr 2025]

<https://www.path.org/media-center/>

*Newsroom [Selected]*

**Boosting advanced-stage clinical trial capacity in East and Central Africa to combat regional epidemic threats**

*The CEPI-backed Research Preparedness Program in East and Central Africa aims to bolster regional clinical trial capacity and disease outbreak readiness.*

March 31, 2025

**Sabin Vaccine Institute** [to 05 Apr 2025]

<https://www.sabin.org/press/>

*Latest News & Press Releases*

*No new digest content identified.*

**UNAIDS** [to 05 Apr 2025]

<http://www.unaids.org/en>

*News, Stories, Updates*

*Feature Story*

**Groundbreaking ruling in Spain overturns discrimination based on HIV status**

04 April 2025

**UNICEF** [to 05 Apr 2025]

<https://www.unicef.org/media/press-releases>

*Latest press releases, news notes and statements [Selected]*

*Press release 05 April 2025*

**More than a million children in the Gaza Strip deprived of lifesaving aid for over one month**

AMMAN, 5 April 2025 – , The blockade of humanitarian aid is having terrible consequences for one million children in the Gaza Strip. No aid has been allowed into the Gaza Strip since 2 March 2025 – representing the longest period of aid blockage since the start of the war – leading to shortages of food, safe water...

**Unitaid** [to 05 Apr 2025]

<https://unitaid.org/>

*Featured News*

*No new digest content identified*

**Vaccine Equity Cooperative [nee Initiative]** [to 05 Apr 2025]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 05 Apr 2025]

<https://www.vaccineacceptance.org/>

*News*

*No new digest content identified.*

**Vaccine Confidence Project** [to 05 Apr 2025]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 05 Apr 2025]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

**[Vaccine Update Newsletter March 2025](#)**

**Wellcome Trust** [to 05 Apr 2025]

<https://wellcome.org/news/all>

*News. Opinion, Reports*

*No new digest content identified.*

**The Wistar Institute** [to 05 Apr 2025]

<https://www.wistar.org/news/press-releases>

*Press Releases*

*No new digest content identified.*

**World Bank** [to 05 Apr 2025]

<http://www.worldbank.org/en/news/all>

*All News [Selected]*

*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 05 Apr 2025]

<https://www.wfpha.org/>

*Blog, Events*

*No new digest content identified.*

**World Medical Association [WMA]** [to 05 Apr 2025]

<https://www.wma.net/news-press/press-releases/>

*Press Releases*

*No new digest content identified.*

**World Organisation for Animal Health [OIE]** [to 05 Apr 2025]

<https://www.oie.int/>

*Press Releases, Statements*

*No new digest content identified.*

.....

.....

**ARM [Alliance for Regenerative Medicine]** [to 05 Apr 2025]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

**[ARM Issues Statement on Dr. Peter Marks and the FDA's Office of Therapeutic Products](#)**

March 29, 2025 Washington, DC

Dr. Peter Marks has been a visionary leader, advocate for rare disease patients, and champion of cell and gene therapy (CGT) during his nine-year tenure as the Director of FDA's Center for Biologics Evaluation and Research. He made many significant contributions to the field over the years and will be missed...

**BIO** [to 05 Apr 2025]

<https://www.bio.org/press-releases>

*Press Releases*

*No new digest content identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 05 Apr 2025]

<http://www.dcvmn.org/>

*News; Upcoming events*

March 28, 2025

**[DCVMN CEO Meets with Chinese Member Companies](#)**

**ICBA – International Council of Biotechnology Associations** [to 05 Apr 2025]

<https://internationalbiotech.org/news/>

*News*

*No new digest announcements identified.*

**IFPMA** [to 05 Apr 2025]

<https://ifpma.org/>

*News, Statements [Selected]*

*Statement 5 Apr 2025*

**[Biopharmaceutical CEO Roundtable gathers in London, focusing on global health challenges and role of pharmaceutical innovation](#)**

04 APRIL 2025, London – This week, the Biopharmaceutical CEO Roundtable (BCR), which represents the world's leading biopharmaceutical companies, met with the UK Prime Minister, senior UK Cabinet Ministers and key officials to discuss strengthening global health policies and sustaining the global policy frameworks that drive pharmaceutical innovation and translate scientific progress into medicines and vaccines...

**International Alliance of Patients' Organizations – IAPO** [to 05 Apr 2025]

<https://www.iapo.org.uk/news>

*Press and media [Selected]*

*No new digest announcements identified.*

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest announcements identified.*

**PhRMA** [to 05 Apr 2025]

<http://www.phrma.org/>

Press Releases

*No new digest announcements identified.*

.....  
.....

## ***Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements***

**AstraZeneca**

Press Releases - *No new digest content identified.*

**Bavarian Nordic**

Latest News

March 31, 2025

### **Bavarian Nordic Receives U.S. FDA Approval of Freeze-Dried Smallpox and Mpox Vaccine**

COPENHAGEN, Denmark, March 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the U.S. Food and Drug Administration (FDA) has approved the freeze-dried formulation of JYNNEOS® (Smallpox and Mpox Vaccine, Live, Non-replicating) for prevention of smallpox and mpox disease in adults 18 years of age and older. This approval will provide additional flexibility for stockpiling against a smallpox event or mpox outbreak...

**Bharat Biotech**

Press Releases - *No new digest announcements identified*

**BioCubaFarma** – Cuba

Últimas Noticias - *No new digest announcements identified.*

**Biological E**

News - *No new digest announcements identified.*

**BioNTech**

Press Releases - *No new digest announcements identified.*

**Boehringer**

Press Releases

### **Boehringer Ingelheim reaches more patients in 2024 and prepares new medicine launches**

Ingelheim, Germany, Wed, 02/04/2025 - 10:30

- Number of patients reached in 2024 jumps 8% to 66 million
- R&D investments rise to EUR 6.2 billion, 23.2% of group net sales
- Company prepares new product launches starting in 2025

**CanSinoBIO**

News - *Website not responding at inquiry*

**CIGB**

Latest News - *No new digest announcements identified.*

## **CinnaGen**

Recent News - No new digest announcements identified.

## **Clover Biopharmaceuticals – China**

News - No new digest announcements identified.

## **Curevac**

News - No new digest announcements identified.

## **Gamaleya National Center/Sputnik**

Latest News and Events - No new digest announcements identified [Last: 09 Nov 2020]

<https://sputnikvaccine.com/> - No new digest announcements identified [Last: 31 Aug 2022]

## **GSK**

Press releases for media - No new digest announcements identified.

## **EuBiologics, S Korea**

News - No new digest announcements identified.

## **IMBCAMS, China**

Home - Website not responding at inquiry.

## **JNJ Innovative Medicine [Janssen]**

Press Releases

[\*\*Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership\*\*](#)

April 2, 2025 United States

## **Merck**

News releases

## **Moderna**

Press Releases

March 31, 2025

[\*\*Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults\*\*](#)

## **Nanogen**

News - No new digest announcements identified

## **Novartis**

News - No new digest announcements identified.

## **Novavax**

Press Releases

Apr 2, 2025

Statement COVID-19

[\*\*Update on U.S. FDA BLA for Novavax's COVID-19 Vaccine\*\*](#)

## **Pfizer**

Recent Press Releases

04.01.2025

**[European Commission Approves Pfizer's RSV Vaccine ABRYOVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease](#)**

**R-Pharm**

<https://rpharm-us.com/index.php>

*[No news or media page identified]*

**Sanofi Pasteur**

[Press Releases](#) - No new digest announcements identified.

**Serum Institute**

[News & Announcements](#) - No new digest announcements identified.

**Sinopharm/WIBPBIBP**

[News](#) - No new digest announcements identified.

**Sinovac**

[Press Releases](#) - No new digest announcements identified.

**SK Biosciences**

[Press Releases](#) - No new digest announcements identified.

**Takeda**

[Newsroom](#) - No new digest announcements identified.

**Valneva**

[Press Releases](#)

April 1, 2025

**[Valneva's Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above](#)**

March 31, 2025

**[Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA](#)**

**Vector State Research Centre of Virology and Biotechnology**

[Home](#) - *[Website not responding [404 error]]*

**WestVac Biopharma**

[Media](#) - No new digest announcements identified.

**Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[Website](#) *[No News/Announcements page identified]*

.....  
.....

***[Contents \[click to move among sections\]](#)***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [\*Pre-Print Servers\*](#)

.....  
.....

### ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **AJOB Empirical Bioethics**

Volume 16, 2025 Issue 1

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

### **AMA Journal of Ethics**

March 2025 Volume 27, Number 3: E167-236

<https://journalofethics.ama-assn.org/issue/regret-moral-psychology-surgical-professionalism>

#### ***Issue Theme: Surgical Care of Incarcerated Patients***

The United States incarcerates more people per capita than any other nation. Developing and maintaining clinically and ethically appropriate surgical care for incarcerated individuals requires clinicians, health care organizations, and governments to actively resist historically entrenched patterns of devaluing incarcerated individuals' humanity and personhood. Neglect of carceral patients' surgical care needs, in particular, remains systematized to the persistent detriment of incarcerated individuals' perioperative and surgical care, recovery, outcomes, and overall health. Carceral surgical patients' risk/benefit profiles must be contextualized at every stage of their care by their diminished legal agency, restricted liberty, and increased environmental risk for a range of abuses and trauma. Carceral surgical patients' vulnerabilities can be exacerbated by uncertainty or conflict about the scope and applicability of state authority relative to clinicians' authority, which can manifest in fraught interactions among clinicians, law enforcement and security personnel, and carceral facility employees tasked with monitoring incarcerated individuals outside carceral settings.

[Reviewed earlier]

### **American Journal of Human Genetics**

Apr 03, 2025 Volume 112 Issue 4 p725-964

<https://www.cell.com/ajhg/current>

#### ***This month in The Journal***

Alyson B. Barnes, Sara B. Cullinan

Genomic medicine has the potential to transform lives, but its integration into healthcare systems requires organization, coordination of regional and national efforts, and consistent funding. Moreover, the many different cultures and political structures, as well as health and health-care disparities, present around the world pose challenges to the adoption of a one-size-fits-all genomics program. Yet, the goals of improving health outcomes by meeting the specific needs of the community in a sustainable and equitable manner are shared by many national and international programs.

*Perspective*

**The expanding global genomics landscape: Converging priorities from national genomics programs**

Caitlin Howley, et al.

As the global landscape of genomics continues to expand, evaluation is needed to inform the design of current and future genomics initiatives. Six key priorities emerged from reviewing and synthesizing information on several national genomics programs. This contributes to the knowledge base and highlights a range of approaches being implemented.

**American Journal of Infection Control**

April 2025 Volume 53 Issue 4 p415-536

<http://www.ajicjournal.org/current>

[New issue; No digest content identified]

**American Journal of Preventive Medicine**

April 2025 Volume 68 Issue 4 p645-858

<https://www.ajpmonline.org/current>

*Research Articles*

**Early Childhood Vaccination Coverage and Patterns by Rural–Urban Commuting Area**

Sophia R. Newcomer, et al.

Published online: January 13, 2025

p773-783

**American Journal of Public Health**

April 2025 115(S1)

<http://ajph.aphapublications.org/toc/ajph/current>

[New issue; No digest content identified]

**American Journal of Tropical Medicine and Hygiene**

Volume 112 (2025): Issue 4 (Apr 2025)

<https://www.ajtmh.org/view/journals/tpmd/112/4/tpmd.112.issue-4.xml>

[New issue; No digest content identified]

**Annals of Internal Medicine**

March 2025 Volume 178, Issue 3

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

**Artificial Intelligence – An International Journal**

Volume 340 March 2025

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/340/suppl/C>

[Reviewed earlier]

**BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>  
(Accessed 05 Apr 2025)  
[No new digest content identified]

### **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>  
(Accessed 05 Apr 2025)

#### **[Community pharmacy workforce willingness, readiness, and infrastructural capacity to deliver vaccination services: a cross-sectional survey in Nigeria](#)**

*There is a growing need for community pharmacists to support universal health coverage by providing vaccination services to address low coverage, as they are among the most accessible healthcare professionals....*

Authors: Adewale Aderemi Oladigbolu, Ukamaka Gladys Okafor, Charles Oluwale Oluwaseyi and Omokhafa Mary Ashore

Citation: *BMC Health Services Research* 2025 25:485

Content type: Research Published on: 2 April 2025

### **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>  
(Accessed 05 Apr 2025)

#### **[Overcoming HPV vaccine hesitancy: insights from a successful school-based vaccination campaign in the Saa health district of Cameroon](#)**

*Vaccination against human papillomavirus (HPV) represents a critical strategy in the global effort to eradicate cervical cancer. Nonetheless, the uptake of HPV vaccination in Cameroon has been slow, resulting ...*

Authors: Eposi C. Haddison, Doris B. Engoung, Carole B. Bodo and Victor M. Njie

Citation: *BMC Infectious Diseases* 2025 25:465

Content type: Research Published on: 4 April 2025

### **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>  
(Accessed 05 Apr 2025)  
[No new digest content identified]

### **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>  
(Accessed 05 Apr 2025)  
[No new digest content identified]

### **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>  
(Accessed 05 Apr 2025)  
[No new digest content identified]

### **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 05 Apr 2025)

**Demand planning for vaccinations using the example of seasonal influenza vaccination - country comparison and implications for Germany**

*Annual vaccination is the most important measure to prevent influenza infection. However, demand planning of influenza vaccines is challenging due to seasonal adaptations of virus strains and long production t...*

Authors: Anna Bußmann, Christian Speckemeier, Pauline Schlesiger, Jürgen Wasem, Isabelle Bekeredjian-Ding and Bernhard Ultsch

Citation: *BMC Public Health* 2025 25:1281

Content type: Research Published on: 4 April 2025

**The structural and organizational aspects of human papillomavirus vaccine affecting immunization coverage in Europe: a systematic review**

*The introduction of HPV vaccinations, that can prevent most prevalent HPV-related cancers of various body districts, is a public health milestone. Despite broad immunization programs, European Health Systems f...*

Authors: Ronan Lemwel Valdecantos, Michele Sorrentino, Michelangelo Mercogliano, Vincenzo Giordano, Ugo Trama, Maria Triassi and Raffaele Palladino

Citation: *BMC Public Health* 2025 25:1254

Content type: Systematic Review Published on: 3 April 2025

**Factors influencing vaccine hesitancy toward non-covid vaccines in South Asia: a systematic review**

*Declared as one of the ten most pressing threats to global health in 2019, the complexity around vaccine acceptance and hesitancy has once again gained great momentum following the COVID-19 pandemic. Lack of v...*

Authors: Sophie C.W. Stuetzle, Matthew Willis, Ewelina Julia Barnowska, Ann-Kristin Bonkass and Anil Fastenau

Citation: *BMC Public Health* 2025 25:1246

Content type: Systematic Review Published on: 2 April 2025

**Barriers, facilitators, needs, and preferences in seeking information regarding cervical cancer prevention programs among Turkish, Moroccan, and Syrian immigrant women: a scoping review**

*Cervical cancer (CC) is the fourth most frequently diagnosed cancer in women worldwide. Immigrant women are often disproportionately affected by CC but show low participation in CC screening and human papillomavirus (HPV) vaccination...*

Authors: Tharsini Veeravagu, Nora Hamdiui, Mart L. Stein, Rik Crutzen and Aura Timen

Citation: *BMC Public Health* 2025 25:1242

Content type: Systematic Review Published on: 2 April 2025

**BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 05 Apr 2025)

[No new digest content identified]

**BMJ Evidence-Based Medicine**

April 2025 - Volume 30 - 2

<https://ebm.bmj.com/content/30/2>

[Reviewed earlier]

## **BMJ Global Health**

March 2025 - Volume 10 - 3

<https://gh.bmj.com/content/10/3>

[Reviewed earlier]

## **Bulletin of the World Health Organization**

2025 Mar 1; 103(3)

<https://www.who.int/publications/journals/bulletin/>

[Reviewed earlier]

## **Cell**

Apr 03, 2025 Volume 188 Issue 7 p1747-2042

<https://www.cell.com/cell/current>

[New issue; No digest content identified]

## **Child Care, Health and Development**

Volume 51, Issue 2 March 2025

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

## **Clinical Pharmacology & Therapeutics**

Volume 117, Issue 4 Pages: 859-1148 April 2025

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

### ***Bench to Budget***

*Editorial*

### **[Bench to Budget: Integrated Evidence Generation for Medications](#)**

Sebastian Schneeweiss, Rebecca Miksad

Pages: 869-871

First Published: 20 March 2025

*State of the Art Review*

### **[Modern Evidence Generation on Medication Effectiveness and Safety During Pregnancy: Study Design Considerations](#)**

Krista F. Huybrechts, Brian T. Bateman, Sonia Hernández-Díaz

Pages: 895-909

First Published: 05 March 2025

## **Clinical Therapeutics**

April 2025 Volume 47 Issue 4 p249-336

<http://www.clinicaltherapeutics.com/current>

[New issue; No digest content identified]

## **Clinical Trials**

Volume 22 Issue 1, February 2025

<https://journals.sagepub.com/toc/ctja/22/1>  
[Reviewed earlier]

### **Conflict and Health**

<http://www.conflictandhealth.com/>  
[Accessed 05 Apr 2025]  
[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 150 March 2025  
<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/150/suppl/C>  
[Reviewed earlier]

### **The CRISPR Journal**

Volume 8, Issue 1 / February 2025  
<https://www.liebertpub.com/toc/crispr/8/1>  
[Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 13, Issue 1 December 2025  
<https://link.springer.com/journal/40142/volumes-and-issues/13-1>  
[Reviewed earlier]

### **Current Medical Research and Opinion**

Volume 41, Issue 1 2025  
<https://www.tandfonline.com/toc/icmo20/current>  
[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

April 2025 - Volume 38 - Issue 2  
<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>  
[Reviewed earlier]

### **Current Protocols in Human Genetics**

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>  
[Accessed 05 Apr 2025]  
[No new digest content identified]

### **Developing World Bioethics**

Volume 25, Issue 1 Pages: 1-79 March 2025  
<https://onlinelibrary.wiley.com/toc/14718847/current>  
[Reviewed earlier]

**Development in Practice**

Volume 34, Issue 6, 2024

<https://www.tandfonline.com/toc/cdip20/34/6>

[Reviewed earlier]

**Development Policy Review**

Volume 43, Issue 3 May 2025

<https://onlinelibrary.wiley.com/toc/14677679/current>

[New issue; No digest content identified]

**Disaster Medicine and Public Health Preparedness**

Volume 19 - 2025

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[New issue; No digest content identified]

**Disasters**

Volume 49, Issue 1 January 2025

<https://onlinelibrary.wiley.com/toc/14677717/2025/49/1>

[Reviewed earlier]

**eBioMedicine**

Volume 114 In progress (April 2025)

<https://www.sciencedirect.com/journal/ebiomedicine/vol/113/suppl/C>

[Reviewed earlier]

**EMBO Reports**

Volume 26 Issue 6 24 March 2025

<https://www.embopress.org/toc/14693178/current>

[New issue; No digest content identified]

**Emerging Infectious Diseases**

Volume 31, Number 2—February 2025

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

**Epidemics**

Volume 50 March 2025

<https://www.sciencedirect.com/journal/epidemics/vol/50/suppl/C>

[Reviewed earlier]

**Epidemiology and Infection**

Volume 153 - 2025

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

### **Ethics & Human Research**

Volume 47, Issue 1 Pages: 1-45 January–February 2025

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Moral distress in clinical research • Research with incarcerated and homeless women***

[Reviewed earlier]

### **Ethics & International Affairs**

Volume 38 - Issue 3 - Fall 2024

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

### **Ethics, Medicine and Public Health**

Volume 32 2024

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/32/suppl/Cc>

[Reviewed earlier]

### **The European Journal of Public Health**

Volume 35, Issue 1, February 2025

<https://academic.oup.com/eurpub/issue/35/1>

[Reviewed earlier]

### **Expert Review of Vaccines**

Volume 24, 2025 Issue 1

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

### **Foreign Affairs**

January/February 2025

<https://www.foreignaffairs.com/issues/2025/104/1>

*Special Section*

***Will Trump Change the World?***

### **Forum for Development Studies**

Volume 52, 2025 - Issue 1

<http://www.tandfonline.com/toc/sfds20/current>

***Co-creating knowledge in development studies***

[Reviewed earlier]

### **Frontiers in Medicine**

<https://www.frontiersin.org/journals/medicine/volumes?volume-id=1463>

[Accessed 05 Apr 2025]

[No new digest content identified]

**Gene Therapy – Nature**

Volume 32 Issue 2, March 2025

<https://www.nature.com/gt/volumes/32/issues/2>

[Reviewed earlier]

**Genetics in Medicines**

Volume 27, Issue 3 March 2025

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/27/issue/3>

[Reviewed earlier]

**Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 05 Apr 2025]

[No new digest content identified]

**Global Health Action**

Volume 18, Issue 1 (2025)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

**Global Health: Science and Practice (GHSP)**

Vol. 12, No. 6 December 20, 2024

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

**Global Legal Monitor & Legal Reports – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>

[https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date\\_desc](https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+law+library+of+congress%29&sb=date_desc)

[Accessed 05 Apr 2025]

[No new digest content identified]

**Global Public Health**

Volume 20, Issue 1 (2025)

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

**Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 05 Apr 2025]

[No new digest content identified]

## **Health and Human Rights**

Volume 26, Issue 2, December 2024

<https://www.hhrjournal.org/volume-26-issue-2-december-2024/>

***Special Section: Distress Migration and the Right to Health***

[Reviewed earlier]

## **Health Economics, Policy and Law**

Volume 19 - Issue 4 - October 2024

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

## **Health Policy and Planning**

Volume 40, Issue 3, April 2025

<https://academic.oup.com/heapol/issue/40/3>

[Reviewed earlier]

## **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 05 Apr 2025]

[No new digest content identified]

## **Human Gene Therapy**

Volume 36, Issue 5-6 / March 2025

<https://www.liebertpub.com/toc/hum/36/5-6>

[Reviewed earlier]

## **Humanitarian Practice Network**

<https://odihpn.org/>

*Featured Publications*

[No new digest content identified]

## **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 21 Issue 1, 2025

<https://www.tandfonline.com/toc/khvi20/21/1?nav=tocList>

*Selected Content*

*Article*

**[COVID-19 vaccine knowledge and acceptance among the Libyan population: A cross-sectional study](#)**

Rana H. Shembesh, Mohammed S. Beshr & Mariam M. ALTarhouni

Article: 2439590

Published online: 19 Dec 2024

*Article*

**[Uptake and service preferences of human papillomavirus vaccination in men who have sex with men](#)**

Rui Zhang, Ngai Sze Wong, Sze Long Chung, Chi Keung Kwan, Tsz Ho Kwan & Shui Shan Lee

Article: 2440956  
Published online: 22 Dec 2024

*Article*

**Visual analysis of the research frontiers, hotspots and development trends of immunization programs for women and children**

Jiachen Zhang, Yani Zhang, Litao Zhang, Jiaxing Wang, Xinheng Qu, Mu Li, Ruochen Zhang, Bo Zhang, Yuqing Zhang & Jianping Zhou

Article: 2442508  
Published online: 09 Jan 2025

*Review Article*

**Rotavirus vaccine coverage, completion, and compliance: A systematic literature review**

Halima Tahrat, Ali Munir & Federico Marchetti

Article: 2442780  
Published online: 03 Jan 2025

*Article*

**Socioeconomic disparities in childhood vaccine hesitancy among parents in China: The mediating role of social support and health literacy**

Xuelin Yao, Mao Fu, Jin Peng, Da Feng, Yue Ma, Yifan Wu, Liuxin Feng, Yu Fang & Minghuan Jiang

Article: 2444008  
Published online: 08 Jan 2025

*Meeting Report*

**Strategies for introducing and implementing vaccines for adults into national immunization programs in Europe: Good practices and key insights of the adult immunization board meeting**

Sara Boccalini, Angela Bechini, Marco Del Riccio, Birgit Weinberger, Jacek Wysocki, Domenico Martinelli, Ole Wichmann, Tiina Likki, Greet Hendrickx, Pierre Van Damme, Chloé Wyndham-Thomas, Paolo Bonanni & Jade Pattyn

Article: 2451487  
Published online: 17 Jan 2025

**Immunity**

Mar 11, 2025 Volume 58 Issue 3 p515-766  
<https://www.cell.com/immunity/current>  
[Reviewed earlier]

**Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>  
[Accessed 05 Apr 2025]  
[No new digest content identified]

**Infectious Diseases of Poverty**

<http://www.idpjournals.com/content>  
[Accessed 05 Apr 2025]  
[No new digest content identified]

### **International Health**

Volume 17, Issue 2, March 2025

<https://academic.oup.com/inthealth/issue/17/2>

[Reviewed earlier]

### **International Human Rights Law Review**

Volume 13 (2024): Issue 2 (Dec 2024)

<https://brill.com/view/journals/hrlr/13/2/hrlr.13.issue-2.xml>

[Reviewed earlier]

### **International Journal of Community Medicine and Public Health**

Vol. 12 No. 4 (2025): April 2025

<https://www.ijcmph.com/index.php/ijcmph/issue/view/123>

*Original Research Articles*

#### **[Strategies to improve uptake of the RTS, S malaria vaccine in a malaria endemic area of Western Kenya](#)**

Irine Okanda, Emily Abuonji, Winnie Majanga, Mevis Omollo, Evalyne Otieno, George Ayodo, Simon Kariuki

1603-1610

DOI: [10.18203/2394-6040.ijcmph20250903](https://doi.org/10.18203/2394-6040.ijcmph20250903)

### **International Journal of Epidemiology**

Volume 54, Issue 1, February 2025

<https://academic.oup.com/ije/issue/54/1>

[Reviewed earlier]

### **International Journal of Human Rights in Healthcare**

Volume 18 Issue 1 2025

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/18/iss/1>

*Table of contents*

[Reviewed earlier]

### **JAMA**

April 1, 2025, Vol 333, No. 13, Pages 1101-1184

<https://jamanetwork.com/journals/jama/currentissue>

*Editorial*

February 20, 2025

#### **[Reaffirming the JAMA Network Commitment to the Health of Patients and the Public](#)**

Kirsten Bibbins-Domingo, PhD, MD, MAS<sup>1</sup>; Robert O. Bonow, MD, MS<sup>2</sup>; Neil M. Bressler, MD<sup>3</sup>; et al  
Linda Brubaker, MD, MS<sup>4</sup>; Dimitri Christakis, MD, MPH<sup>5</sup>; Stacy L. Christiansen, MA<sup>6</sup>;  
Gregory Curfman, MD<sup>7</sup>; Mary L. (Nora) Disis, MD<sup>8</sup>; Annette Flanagan, RN, MA<sup>9</sup>; Sandro Galea, MD,  
DrPH<sup>10</sup>; Sharon K. Inouye, MD, MPH<sup>11</sup>; S. Andrew Josephson, MD<sup>12</sup>; Melina R. Kibbe, MD<sup>13</sup>; Tracy  
A. Lieu, MD, MPH<sup>4</sup>; Preeti N. Malani, MD, MS<sup>14</sup>; Mary M. McDermott, MD<sup>4</sup>; Christopher C. Muth, MD<sup>4</sup>;  
Dost Öngür, MD, PhD<sup>14</sup>; Hannah Park<sup>15</sup>; Jay F. Piccirillo, MD<sup>16</sup>; Eli N. Perencevich, MD, MS<sup>17</sup>; Roy  
H. Perlis, MD, MSc<sup>18</sup>; Joseph S. Ross, MD<sup>4</sup>; Kanade Shinkai, MD, PhD<sup>19</sup>; Kristin L. Walter, MD, MS<sup>4</sup>  
JAMA. 2025;333(13):1121-1122. doi:10.1001/jama.2025.2405

In the first month of the new administration responsible for leading the US, the executive branch has issued a flurry of orders, including ones associated with the dismissal or resignation of tens of thousands of federal employees. Many of these have substantial consequences for science, medicine, and public health. Amidst the dizzying array of actions, it is difficult to know where to focus and how best to respond.<sup>1,2</sup> However, the silencing of science and health-related communications through suppression or erasure of information, and the corresponding silence by many in the fields of biomedicine and public health, deserve special consideration.

Multiple infectious threats remain active across the globe, but the US Centers for Disease Control and Prevention has been prohibited from communicating with other public health agencies, such as the World Health Organization, to coordinate a response and from advising the public about the nature of these threats and how to best take protective action.<sup>3</sup> US Department of Health and Human Services (HHS) websites that contain health surveillance data, details on enrollment in clinical trials, and other critical information to guide clinical decision-making have been taken down or expunged. Although a number have been ordered to return to service, some of these sites bear an ideological disclaimer that is unrelated to health. For example, one site currently states, "Per a court order, HHS is required to restore this website as of 11:59PM ET, February 11, 2025. Any information on this page promoting gender ideology is extremely inaccurate and disconnected from the immutable biological reality that there are two sexes, male and female. The Trump Administration rejects gender ideology and condemns the harms it causes to children, by promoting their chemical and surgical mutilation, and to women, by depriving them of their dignity, safety, well-being, and opportunities. This page does not reflect biological reality and therefore the Administration and this Department rejects it."<sup>4</sup>

Some authors of scientific works in process have had to remove their names from publications for these publications to proceed; others have chosen to pause or withdraw their publications. While some of these actions are directly related to the executive order to HHS employees to cease communications, many have been undertaken preemptively by authors who are not subject to the order but are presumably fearful of the challenges of communicating complex findings in this current environment. Some authors are engaging in anticipatory compliance by scrubbing from their manuscripts words they fear may be deemed, in the moment, politically unacceptable. Some have done this because they have been ordered to do so and others have been propelled by perhaps justifiable fear that in this environment, their association with the concepts underlying these words could well mean loss of employment, loss of funding, or other retaliatory action in the future.

Until the recent draconian reductions in indirect cost rates for federally funded grants that support needed research and infrastructure at academic medical centers,<sup>5,6</sup> the response of most biomedical institutions to the ongoing actions threatening scientific integrity and the health of the public had been muted. Presumably, this subdued response stemmed from an interest in these institutions maintaining a nonpartisan stance for fear of retribution. While many are calling attention to the harms to health research that would be caused by such substantial cost reductions and a judicial hold has been placed, disruptive uncertainty continues.<sup>6</sup>

The free exchange of ideas is essential to scientific progress, just as it is integral to the founding ideals of the US. The integrity of the scientific process does not depend on blind trust in science or on an assumption that a scientific finding is always right. Rather, this integrity hinges on the confidence that the free exchange of scientific ideas grounded in rigorously conducted scientific inquiry, including the discussion, debate, and disagreement that results in further inquiry, ultimately leads to insights that are likely to be true. For those of us who are part of the biomedical enterprise, the silencing of this scientific discourse and the prohibition of communication of information for patients and clinicians directly threaten the professional oaths that many have taken to protect the health of patients and the

public. The silence with which many of us and our institutions are meeting this moment must be challenged.

As leaders of JAMA and the JAMA Network, we offer these core commitments.

First, we reaffirm the principles and values found on our mastheads that have held us in good stead for decades. At JAMA, our mission is to advance the science and art of medicine and the betterment of public health, and includes specific objectives to “maintain the highest standards of editorial integrity and quality independent of any special interests,” “to foster responsible and balanced debate on important issues that affect medicine, health, health care, and health policy,” and “the social responsibility to improve equity and the total human condition, promulgate truth in science and medicine, and promote the integrity of science.”<sup>7</sup> Our commitment to diversity of thought, expertise, and background on our teams and to aim for the highest integrity in the editorial process are essential to ensuring the open scientific dialogue and exchange of ideas that are core to robust scientific discourse.<sup>8</sup>

Second, we remain steadfast in our guidance to authors and readers across the JAMA Network journals<sup>9</sup> and endorse and adhere to the standards set by the International Committee of Medical Journal Editors.<sup>10</sup> We also recognize the realities of the current environment and the specific injunctions some authors may be under and the broader concerns of others. We are committed to working with authors to publish in accordance with the highest standards for scientific and editorial integrity. We will act flexibly, where appropriate, to ensure that censoring efforts will not silence the integrity of the scientific process or clear communication of scientific information important for health. Authors and editors have a shared goal of ensuring the broad and faithful dissemination of scientific findings, and we will strive to pursue this goal regardless of the external environment.

The JAMA Network publishes science, opinion, and educational materials with the foundational goal of advancing health. JAMA Network journals have always aspired to provide essential health information to guide both science and clinical practice, and we will continue to do so, even in the setting of real and perceived challenging government actions. We shall, as an editorial team, stay abreast of changes in this very dynamic environment and adapt as needed to ensure that we will continue to meet the needs of science and health communication, guided always by our responsibility to the health of patients and the public worldwide.

### **JAMA Health Forum**

April 2025, Vol 6, No. 4

<https://jamanetwork.com/journals/jama-health-forum/issue>

[New issue; No digest content identified]

### **JAMA Pediatrics**

March 2025, Vol 179, No. 3, Pages 228-356

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[Reviewed earlier]

### **JB1 Evidence Synthesis**

March 2025 - Volume 23 - Issue 3

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

### **Journal of Adolescent Health**

March 2025 Volume 76 Issue 3 p341-526

<https://www.jahonline.org/current>

[Reviewed earlier]

### **Journal of Artificial Intelligence Research**

Vol. 82 (2025)

<https://www.jair.org/index.php/jair>

*Contents*

[New issue; No digest content identified]

### **Journal of Community Health**

Volume 50, Issue 1 February 2025

<https://link.springer.com/journal/10900/volumes-and-issues/50-1>

[Reviewed earlier]

### **Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*

Vol. 8 No. 01 (2025)

<https://www.cmro.in/index.php/jcmro/issue/view/91>

[Reviewed earlier]

### **Journal of Development Economics**

Volume 174 May 2025

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/174/suppl/C>

*Research article Open access*

**[Beyond the records: Data quality and COVID-19 vaccination progress in low- and middle-income countries](#)**

Yannick Markhof, Philip Wollburg, Alberto Zezza

Article 103449

*Short communication Abstract only*

**[Can SMS interventions increase vaccination? Evidence from the COVID-19 pandemic in Kenya](#)**

Kevin Carney, Leah R. Rosenzweig, Wendy N. Wong, Florence Akech, ... Elisa M. Maffioli

Article 103469

### **Journal of Empirical Research on Human Research Ethics**

Volume 19 Issue 4-5, October–December 2024

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

### **Journal of Epidemiology & Community Health**

March 2025 - Volume 79 - 3  
<https://jech.bmj.com/content/79/3>  
[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 18, Issue 1 March 2025  
<https://onlinelibrary.wiley.com/toc/17565391/current>  
[Reviewed earlier]

**Journal of Global Ethics**

Volume 20, Issue 3 (2024)  
<http://www.tandfonline.com/toc/rjge20/current>  
***Special Issue: 20th Anniversary Forum***  
[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 36, Number 1, February 2025  
<https://muse.jhu.edu/issue/54278>  
*Table of Contents*  
[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 27, Issue 1 February 2025  
<https://link.springer.com/journal/10903/volumes-and-issues/27-1>  
[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 23, Issue 1 (2025)  
<https://www.tandfonline.com/toc/wimm20/current>  
[Reviewed earlier]

**Journal of International Development**

Volume 37, Issue 2 Pages: 1-619 March 2025  
<https://onlinelibrary.wiley.com/toc/10991328/current>  
[Reviewed earlier]

**Journal of Medical Ethics**

April 2025 - Volume 51 - 4  
<http://jme.bmj.com/content/current>  
*Extended essays*  
**[Justification of principles for healthcare priority setting: the relevance and roles of empirical studies exploring public values](#)** (22 February, 2023)  
Erik Gustavsson, Lars Lindblom

### **Journal of Patient-Centered Research and Reviews**

Volume 11, Issue 3 (2024)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

### **The Journal of Pediatrics**

Volume 277 February 2025

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/277/suppl/C>

[Reviewed earlier]

### **Journal of Pharmaceutical Policy and Practice**

Volume 18, 2025 Issue 1

<https://www.tandfonline.com/toc/jppp20/18/1?nav=tocList>

[Reviewed earlier]

### **Journal of Public Health Management & Practice**

March/April 2025 - Volume 31 - Issue 2

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

### **Journal of Public Health Policy**

Volume 46, Issue 1 March 2025

<https://link.springer.com/journal/41271/volumes-and-issues/46-1>

[Reviewed earlier]

### **Journal of the Royal Society – Interface**

April 2025 Volume 22 Issue 225

<https://royalsocietypublishing.org/toc/rsif/current>

[New issue; No digest content identified]

### **Journal of Travel Medicine**

Volume 32, Issue 3, April 2025

<https://academic.oup.com/jtm/issue>

*Editor's Choice*

**[Vaccination perspectives: the Qdenga® dilemma](#)**

Rachael Fletcher and others

*Journal of Travel Medicine*, Volume 32, Issue 3, April 2025, taaf023,

<https://doi.org/10.1093/jtm/taaf023>

The introduction of the Qdenga® dengue vaccine presents both opportunities and challenges. Debate regarding efficacy, safety, and potential risks for dengue-naïve individuals continues. With varying international guidelines and evolving evidence, advising travellers requires detailed risk assessment, up-to-date evidence based decisions, and clear communication.

### **Journal of Virology**

Volume 99 • Number 2 • February 2025

<http://jvi.asm.org/content/current>

[Reviewed earlier]

### **The Lancet**

Apr 05, 2025 Volume 405 Number 10485 p1119-1202

<https://www.thelancet.com/journals/lancet/issue/current>

[New issue; No digest content identified]

### **The Lancet Child & Adolescent Health**

Apr 2025 Volume 9 Number 4 p211-282, e10-e12

<https://www.thelancet.com/journals/lanchi/issue/current>

*Health Policy*

#### **[Simplifying medicine dosing for children by harmonising weight bands across therapeutic areas](#)**

Hylke Waalewijn, et al. and the members of the expert panels

*Summary*

Generally, dose recommendations for children are expressed as fixed dosing increments related to bodyweight, known as weight bands. The weight bands recommended in WHO treatment guidelines vary between diseases, leading to complexity and potential dosing errors when treating children for multiple diseases simultaneously. The introduction of a harmonised weight banding approach for orally administered drugs across disease areas could streamline dosing for young children, but implementing such an approach would require changes in current dosing recommendations. In this Health Policy, we describe the process we conducted to: identify therapeutic areas for harmonisation of weight bands; propose a harmonised weight-banding system to align with current use of weight bands in antibiotic guidance; and simulate the expected effect of dose adjustments due to weight-band harmonisation. Each step of this process, along with the effect and feasibility of weight-band harmonisation was discussed with clinical, policy, and pharmacology experts convened by WHO, representing four therapeutic areas: tuberculosis, HIV, malaria, and hepatitis C. Dosing according to harmonised weight bands across the targeted therapeutic areas was found to be feasible and should be considered for implementation by WHO disease programmes through their appropriate normative processes.

### **Lancet Digital Health**

Apr 2025 Volume 7 Number 4 e232-e294

<https://www.thelancet.com/journals/landig/issue/current>

*Viewpoint*

#### **[The importance of microbiology reference laboratories and adequate funding for infectious disease surveillance](#)**

David Shaw,

*Summary*

Microbiology reference laboratories perform a crucial role within public health systems. This role was especially evident during the COVID-19 pandemic. In this Viewpoint, we emphasise the importance of microbiology reference laboratories and highlight the types of digital data and expertise they provide, which benefit national and international public health. We also highlight the value of surveillance initiatives among collaborative international partners, who work together to share, analyse, and interpret data, and then disseminate their findings in a timely manner. Microbiology reference laboratories have substantial impact at regional, national, and international levels, and sustained support for these laboratories is essential for public health in both pandemic and non-pandemic times.

## **Lancet Global Health**

Apr 2025 Volume 13 Number 4 e599-e777

<https://www.thelancet.com/journals/langlo/issue/current>

*Editorial*

### **Redefining implementation science for global health decolonisation**

The Lancet Global Health

*Comment*

### **A call for an Africa-centric health research ethics framework: a way forward for shaping global health research**

Mosoka Papa Fallah, Nebiyu Dereje, Elvis Temfack, Raji Tajudeen, Jean Kaseya

*Series*

*Clinical Trials in Global Health*

### **Better engagement, better evidence: working in partnership with patients, the public, and communities in clinical trials with involvement and good participatory practice**

Nina Gobat, et al.

*Clinical Trials in Global Health*

### **Strengthening the paediatric clinical trial ecosystem to better inform policy and programmes**

James A Berkley, et al.

*Clinical Trials in Global Health*

### **Advancing maternal and perinatal health through clinical trials: key insights from a WHO global consultation**

Teesta Dey, et al.

*Clinical Trials in Global Health*

### **Democratising clinical trials research to strengthen primary health care**

Christopher C Butler, et al.

*Clinical Trials in Global Health*

### **Reporting summary results in clinical trial registries: updated guidance from WHO**

An-Wen Chan, et al.

## **Lancet Infectious Diseases**

Apr 2025 Volume 25 Number 4 p357-470, e191-e254

<https://www.thelancet.com/journals/laninf/issue/current>

*Editorial*

### **Facts and myths about measles**

The Lancet Infectious Diseases

*Articles*

### **Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine versus a quadrivalent meningococcal conjugate vaccine in adults in India: an observer-blind, randomised, active-controlled, phase 2/3 study**

Prasad S Kulkarni, et al.

### **Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial**

Jaya Goswami, et al. on behalf of the study investigators

**Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis**

Julia C Bennett, et al. the PSERENADE Team

**Lancet Public Health**

Apr 2025 Volume 10 Number 4 e264-e346

<https://www.thelancet.com/journals/lanpub/issue/current>

*Editorial*

**Public health under Trump 2.0: the first 50 days**

The Lancet Public Health

... These past 50 days saw an array of decisions and proposed or paused policies that undermine science and expertise, weaken protection for vulnerable populations, risk worsening health inequities, and threaten public health across the USA and abroad. As a journal dedicated to public health and improving health equity, at The Lancet Public Health we stand for the communities we serve, we will continue to report, document, support researchers and practitioners, and advocate for better health for all.

**Lancet Respiratory Medicine**

Mar 2025 Volume 13 Number 3 p189-288, e17-e19

<https://www.thelancet.com/journals/lanres/issue/current>

*Editorial*

**Pneumonia: a neglected global threat**

The Lancet Respiratory Medicine

... At the intersection between research activities and public health interventions lies the problem of AMR. Bacterial pneumonia can be treated with antibiotics, although deaths attributable to AMR have increased globally for some causative pathogens, such as *Klebsiella pneumoniae*, and are projected to grow.

Another important route to reduce pneumonia is through vaccination. Increasing global coverage of existing vaccines, both those that are part of routine immunisation programmes, such as the pneumococcal conjugate vaccine, and for those at high risk, pneumococcal polysaccharide vaccine, can reduce the risk of contracting pneumonia and thus the need for antimicrobials in clinical practice. In addition, accelerating research on the new generation of vaccines should be a priority to ensure a long-term plan to tackle AMR and develop alternative means of protection.

After more than two centuries since its discovery, pneumonia remains a global health threat, with an upward trajectory. We urgently need a multisectoral effort to reverse this trend and tackle the disease with the support of primary care, public health experts, researchers, and clinicians. The fight against pneumonia is challenging, but with coordinated efforts we can start moving towards a healthier future for all.

**Maternal and Child Health Journal**

Volume 29, Issue 3 March 2025

<https://link.springer.com/journal/10995/volumes-and-issues/29-3>

[Reviewed earlier]

**Medical Decision Making (MDM)**

Volume 45 Issue 3, April 2025

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

## **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 103, Issue 1 Pages: 1-241 March 2025

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

## **Molecular Therapy**

Apr 02, 2025 Volume 33 Issue 4 p1305-1860

<https://www.cell.com/molecular-therapy/current>

### **[In this issue](#)**

Sickle cell disease (SCD) and  $\beta$ -thalassemia are two of the most common  $\beta$ -hemoglobinopathies, genetic diseases that affect the  $\beta$ -globin chains of hemoglobin. A single mutation in  $\beta$ -globin gene (*HBB*) causes the characteristic dysfunctional hemoglobin protein in SCD, while over 300 mutations across *HBB* cause severe anemia and reduced  $\beta$ -globin levels in  $\beta$ -thalassemia. Homology-directed repair (HDR) is a promising approach to restore *HBB* expression. However, HDR can be challenging because the insert cannot be homologous to the endogenous gene, and synonymous codon-optimized, intron-less sequences may be inadequate.

## **Nature**

Volume 640 Issue 8057, 3 April 2025

<https://www.nature.com/nature/volumes/640/issues/8057>

*Editorial* 01 Apr 2025

### **[A brain drain would impoverish the United States and diminish world science](#)**

Europe is advertising itself as a destination for embattled US scientists. It seems many are considering leaving.

## **Nature Biotechnology**

Volume 43 Issue 3, March 2025

<https://www.nature.com/nbt/volumes/43/issues/3>

[Reviewed earlier]

## **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 05 Apr 2025)

[Reviewed earlier]

## **Nature Genetics**

Volume 57 Issue 3, March 2025

<https://www.nature.com/ng/volumes/57/issues/3>

[Reviewed earlier]

## **Nature Human Behaviour**

Volume 9 Issue 3, March 2025

<https://www.nature.com/nathumbehav/volumes/9/issues/2>

[New issue; No digest content identified]

### **Nature Medicine**

Volume 31 Issue 3, March 2025

<https://www.nature.com/nm/volumes/31/issues/3>

[Reviewed earlier]

### **Nature Reviews Drug Discovery**

Volume 24 Issue 4, April 2025

<https://www.nature.com/nrd/volumes/24/issues/4>

*Comment* 16 Dec 2024

#### **[IRDiRC perspectives on the application of digital biomarkers in therapeutic development for rare diseases](#)**

New approaches are needed to streamline clinical trials of drugs for patients with rare diseases. Digital biomarkers offer one such approach, but several challenges must be addressed to realize their potential.

Rajesh Krishna, Anneliene H. Jonker, Daniel O'Connor

### **Nature Reviews Genetics**

Volume 26 Issue 4, April 2025

<https://www.nature.com/nrg/volumes/26/issues/4>

*Comment* 03 Feb 2025

#### **[Integrating ELSI study teams in paediatric genomic research efforts](#)**

The promise of paediatric genomics depends on proactively addressing complex ethical and equity issues with sustained community engagement. Hernandez et al. advocate for the integration of ELSI scholars into paediatric genomic study teams to catalyse timely discovery in genomics.

Raquel G. Hernandez, Simón Guambaña, Melissa A. Faith

### **Nature Reviews Immunology**

Volume 25 Issue 4, April 2025

<https://www.nature.com/nri/volumes/25/issues/4>

[New issue; No digest content identified]

### **New England Journal of Medicine**

Volume 392 No. 13 April 3, 2025

<https://www.nejm.org/toc/nejm/medical-journal>

*Editorials*

#### **[Working at Cross-PURPOSEs to Ending HIV](#)**

G.E. Gray and W.F. Venter

Almost 15 years ago, the results of the Preexposure Prophylaxis Initiative (iPrEx) trial, which showed the efficacy of oral antiretroviral agents as preexposure prophylaxis (PrEP), were reported in the Journal.<sup>1</sup> However, only 15% of persons who would benefit from PrEP currently receive it.<sup>2</sup> The recent modest fall in the global incidence of human immunodeficiency virus (HIV) infection obscures the ongoing epidemic among key populations in high-income, middle-income, and low-income countries, including continued high infection rates among young women in southern Africa. The United Nations 2030 prevention targets will not be met unless something different is done, and soon.

The results of the PURPOSE 2 trial, reported by Kelley et al. in this issue of the Journal<sup>3</sup> essentially mirror those of the PURPOSE 1 trial, which was conducted in Uganda and South Africa. The PURPOSE 1 trial showed near-total protection from HIV infection among participants who received subcutaneous lenacapavir every 6 months.<sup>4</sup>...

#### *Original Articles*

#### **[Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons](#)**

C.F. Kelley and Others

#### **NEJM Evidence**

Volume 4 No. 4 April 2025

<https://evidence.nejm.org/toc/evid/current>

*NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.*

[New issue; No digest content identified]

#### **njp Vaccines**

<https://www.nature.com/npjvaccines/>

[Accessed 05 Apr 2025]

Article 05 Apr 2025

#### **[Modeling the impact of early vaccination in an influenza pandemic in the United States](#)**

Van Hung Nguyen, Pascal Crépey, Jane M. True

#### **Pediatrics**

Volume 155, Issue 3 March 2025

<https://publications.aap.org/pediatrics/issue/155/3>

[Reviewed earlier]

#### **PharmacoEconomics**

Volume 43, Issue 4 April 2025

<https://link.springer.com/journal/40273/volumes-and-issues/43-3>

*Leading Article*

#### **[A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence](#)**

Beth Woods, Alfredo Palacios, Mark Sculpher

31 December 2024 Pages: 363 - 373

#### **PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 05 Apr 2025)

[No new digest content identified]

#### **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 05 Apr 2025)

[No new digest content identified]

### **PLoS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60)

(Accessed 05 Apr 2025)

[No new digest content identified]

### **PLoS Medicine**

<https://journals.plos.org/plosmedicine/>

(Accessed 05 Apr 2025)

[No new digest content identified]

### **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 05 Apr 2025)

#### **[The transdisciplinary research process and participatory research approaches used in the field of neglected tropical diseases: A scoping review](#)**

Norana Abdul Rahman, Vaikunthan Rajaratnam, George L. Burchell, Karen Morgan, Mohamed Rusli Abdullah, Marjolein B. M. Zweekhorst, Ruth M. H. Peters

Research Article | published 01 Apr 2025 PLOS Neglected Tropical Diseases

<https://doi.org/10.1371/journal.pntd.0012959>

### **PLoS One**

<http://www.plosone.org/>

[Accessed 05 Apr 2025]

#### **[Findings from a qualitative analysis: Social media influencers of color as trusted messengers of HPV vaccination messages](#)**

Amelia Burke-Garcia, Erin Cutroneo, Dasha Afanaseva, Kayla Madden, Angela Sustaita-Ruiz, Preethi Selvan, Estefany Rivera Sanchez, Amy Leader

Research Article | published 04 Apr 2025 PLOS ONE

<https://doi.org/10.1371/journal.pone.0319160>

#### **[A dynamic transmission model for assessing the impact of pneumococcal vaccination in the United States](#)**

Tufail M. Malik, Kevin M. Bakker, Rachel J. Oidtman, Oluwaseun Sharomi, Giulio Meleleo, Robert B. Nachbar, Elamin H. Elbasha

Research Article | published 02 Apr 2025 PLOS ONE

<https://doi.org/10.1371/journal.pone.0305892>

### **PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 05 Apr 2025]

[No new digest content identified]

## **PNAS - Proceedings of the National Academy of Sciences of the United States**

April 8, 2025 | vol. 122 | no. 14

<https://www.pnas.org/toc/pnas/122/14>

*Perspective* March 28, 2025

### **Meltdown of trust in weakly governed economies**

Stephen Polasky, Marten Scheffer and John M. Anderies

#### *Abstract*

A well-functioning society requires well-functioning institutions that ensure prosperity, fair distribution of wealth, social participation, security, and informative media. Such institutions are built on a foundation of trust. However, while trust is essential for economic success and good governance, interconnected mechanisms inherent in weakly governed market economies tend to undermine the very trust on which such success depends. These mechanisms include the intrinsic tendency for inequality to grow, media to boost perceived unfairness, and self-interest to gain rewards at the expense of others. These mechanisms, if left unchecked, allow wealth concentration to result in state capture where institutions facilitate further wealth concentration instead of the promoting the common good. As a result, people may become alienated and untrusting of fellow citizens and of institutions. Several democracies now experience such dynamics, the United States being a prime example. We discuss ways in which well-functioning democracies can design institutions to help avoid this social trap, and the much harder challenge of escaping the trap once in it. Successful cases such as the ability of Scandinavian democracies to maintain high-trust, and the US progressive era in the early 20th century provide instructive examples.

## **PNAS Nexus**

Volume 4, Issue 3, March 2025

<https://academic.oup.com/pnasnexus/issue/4/3>

[New issue; No digest content identified]

## **Prehospital & Disaster Medicine**

Volume 40 - Issue 1 - February 2025

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

## **Preventive Medicine**

Volume 192 March 2025

<https://www.sciencedirect.com/journal/preventive-medicine/vol/192/suppl/C>

[Reviewed earlier]

## **Proceedings of the Royal Society B**

March 2025 Volume 292 Issue 2042

<https://royalsocietypublishing.org/toc/rspb/current>

[Reviewed earlier]

## **Public Health**

Volume 240 Pages 1-222 (March 2025)

<https://www.sciencedirect.com/journal/public-health/vol/240/suppl/C>

[Reviewed earlier]

**Public Health Ethics**

Volume 18, Issue 1, April 2025

<http://phe.oxfordjournals.org/content/current>

[New issue; No digest content identified]

**Public Health Genomics**

2025, Vol. 28, No. 1

<https://karger.com/phg/issue/28/1>

[Reviewed earlier]

**Public Health Reports**

Volume 140 Issue 1, January/February 2025

<https://journals.sagepub.com/toc/phrg/140/1>

[Reviewed earlier]

**Qualitative Health Research**

Volume 35 Issue 3, March 2025

<https://journals.sagepub.com/toc/QHR/current>

[Reviewed earlier]

**Research Ethics**

Volume 21 Issue 1, January 2025

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

**Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 05 Apr 2025]

[No new digest content identified]

**Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Latest Articles*

[No new digest content identified]

**Risk Analysis**

Volume 45, Issue 3 Pages: 473-721 March 2025

<https://onlinelibrary.wiley.com/toc/15396924/current>

[New issue; No digest content identified]

**Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 05 Apr 2025]  
[No new digest content identified]

## **Royal Society Open Science**

April 2025 Volume 12 Issue 4

<https://royalsocietypublishing.org/toc/rsos/current>

April 2025 Volume 12 Issue 4

## **Science**

Volume 388| Issue 6742| 4 Apr 2025

<https://www.science.org/toc/science/current>

*In Depth*

### **Killed NIH grants could waste billions of dollars**

BY Sara Reardon

03 Apr 2025: 12-13

More than \$1.4 billion in sunk research costs may produce few results, analysis suggests

### **NSF has awarded almost 50% fewer grants**

BY Jeffrey Mervis

03 Apr 2025: 13-14

An analysis shows a drastic falloff since Trump took office. The finding conflicts with the director's claims

*Policy Forum*

### **Rubella and measles: The beginning of the endgame**

BY Matthew J. Ferrari, William J. Moss

03 Apr 2025: 32-34

*Benchmarks must be established and progress tracked to set a global target and take action*

A September 2024 recommendation from the World Health Organization (WHO) for universal introduction of rubella-containing vaccines (RCVs) into childhood vaccination programs in all countries paves the way to dramatically reduce, and ultimately eradicate, congenital rubella syndrome (CRS), which affects tens of thousands of families each year ([1](#)). It removes a critical barrier to the introduction of rubella vaccination in most of the remaining 19 countries yet to do so. Because rubella vaccine is delivered in combination with measles vaccine and introduction will involve large campaigns to vaccinate all children under 15 years of age, this recommendation provides an opportunity to move much closer to the ultimate goal: a world without measles or rubella. With planning for this goal currently paused, the programmatic, operational, and research communities must come together to establish empirical benchmarks that countries have progressed far enough for a global target to be set and the "endgame" to begin...

## **Science and Engineering Ethics**

Volume 31, Issue 2 April 2025

<https://link.springer.com/journal/11948/volumes-and-issues/31-2>

[Reviewed earlier]

## **Science Translational Medicine**

Volume 17| Issue 792| 2 Apr 2025

<https://www.science.org/toc/stm/current>

[New issue; No digest content identified]

### **Scientific Reports**

<https://www.nature.com/srep/articles?type=article>

[Accessed 05 Apr 2025]

[No new digest content identified]

### **Social Science & Medicine**

Volume 370 April 2025

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/370/suppl/C>

[Reviewed earlier]

### **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 05 Apr 2025]

[No new digest content identified]

### **Theoretical Medicine and Bioethics**

Volume 46, Issue 2 April 2025

<https://link.springer.com/journal/11017/volumes-and-issues/46-2>

[New issue; No digest content identified]

### **Travel Medicine and Infectious Diseases**

Volume 64 March–April 2025

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/64/suppl/C>

[Reviewed earlier]

### **Tropical Medicine & International Health**

Volume 30, Issue 3 Pages: i-iv, 143-230 March 2025

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

### **Vaccine**

Volume 52 11 April 2025

<https://www.sciencedirect.com/journal/vaccine/vol/52/suppl/C>

*Short communication Abstract only*

**[Tropis needle-free injector for fractional-dose IPV administration: A pilot study for integration into routine immunization services in Cuba](#)**

Sonia Resik, Rocio Lopez Cavestany, Alina Tejeda, Manuel Díaz, ... Ondrej Mach

Article 126903

*Short communication Abstract only*

**[COVID-19 vaccination integration, innovations and key populations: Results from a global survey](#)**

Ishani Mathur, Anika Ruisch, Maeve Conlin, Ibironke Oyatoye, ... Christian Suharlim

Article 126863

*Research article Open access*

**[Comparative analysis of fourteen COVID-19 vaccine injury compensation systems and claim approval rates](#)**

Chao-Fang Chu, Tzu-Hao Chang, Jen-Ji Ho

Article 126830

No-fault vaccine injury compensation schemes provide financial redress for adverse effects from vaccines without establishing fault. Due to the rapid vaccine development and distribution, these programs are crucial for vaccinees during the COVID-19 pandemic. Investigating the performance differences of these schemes worldwide and finding a more balanced approach is essential to responses to future pandemics.

*Research article Open access*

**[Global perspectives on COVID-19 vaccination: Impacts on well-being and inequality](#)**

David Leblang, Michael D. Smith, Dennis Wesselbaum

Article 126906

*Research article Abstract only*

**[Parental status and gender are associated with differences in Tdap vaccination rates among United States adults](#)**

Laurie Beth Griffin, Brock E. Polnaszek, Jaejoon Shin, Melissa A. Clark, ... Annie Gjelsvik

Article 126901

*Research article Abstract only*

**[Persistent socioeconomic disparities in childhood vaccination coverage in Tanzania: Insights from multiple rounds of demographic and health surveys](#)**

Anderson Bendera, Keiko Nakamura, Xuan Minh Tri Tran, Ntuli A. Kapologwe, ... Eugene Benjamin Meshi

Article 126904

*Research article Open access*

**[Dynamics of global emergency vaccine stockpiles: A systems analysis and application to cholera](#)**

Donovan Guttieres, Carla Van Riet, Nico Vandaele, Catherine Decouttere

Article 126889

## **Vaccines**

<https://www.mdpi.com/journal/vaccines>

[Accessed 05 Apr 2025]

*Open Access Article*

**[Assessing Immunization Coverage and the Negative Impact of Local Vaccine Production Cessation in Ecuador](#)**

by Esteban Ortiz-Prado, Lissette Carolina Villacreses-Brito, Jorge Vasconez-Gonzalez, Cristina Anabel Jacome, Marlon Arias-Intriago and Juan S. Izquierdo-Condoy

Vaccines 2025, 13(4), 348; <https://doi.org/10.3390/vaccines13040348> - 25 Mar 2025

*Abstract*

Background: The COVID-19 pandemic highlighted vaccine importance while exposing inequities in global immunization, especially in LMICs like Ecuador. Local vaccine production ensures supply, reduces reliance on imports, and boosts health security. Understanding the relationship between local production and vaccination outcomes is crucial to

*Open Access Systematic Review*

**Comparative Analysis of Health Economic Evaluations for Different Influenza Vaccines and Vaccination Strategies in China: A Systematic Review**

by Fanxu Kong, Li Cai, Jiayi Zhang, Huijie Zhu, Zhibin Peng, Jiandong Zheng, Yaming Zheng and Hai Fang

Vaccines 2025, 13(3), 332; <https://doi.org/10.3390/vaccines13030332> - 20 Mar 2025

*Abstract*

Objective: This study systematically reviews health economic evaluations of influenza vaccines in China and synthesizes the evidence on different vaccine categories. Methods: We searched databases, including the China Hospital Knowledge Database, Wanfang, PubMed, Web of Science, and Embase, for studies on the health

**Value in Health**

April 2025 Volume 28 Issue 4 p489-670

<https://www.valueinhealthjournal.com/current>

*Health Policy Analysis*

**Role of Health Equity in Health Technology Assessment Processes: A Landscape Analysis of 13 Health Systems in Asia**

Chanthawat Patikorn, et al.

Published online: February 06, 2025

p582-590

**World Development**

Volume 188 April 2025

<https://www.sciencedirect.com/journal/world-development/vol/188/suppl/C>

*Research article Open access*

**Adapting the Women's empowerment in nutrition index: Lessons from Kenya**

Erin Lentz, Nathan Jensen, Watson Lepariyo, Sudha Narayanan, Elizabeth Bageant

Article 106887

.....  
.....

***Contents [click to move among sections]***

:: [\*Milestones, Perspectives\*](#)

:: [\*WHO\*](#)

:: [\*Organization Announcements\*](#)

:: [\*Journal Watch\*](#)

:: [\*Pre-Print Servers\*](#)

.....  
.....

***Pre-Print Servers***

**arxiv**

<https://arxiv.org/>

[Accessed 05 Apr 2025]

*[Filters: Emerging Technologies; Neural and Evolutionary Computing; Computers and Society; Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology; General Economics]*

[arXiv:2504.01043](https://arxiv.org/abs/2504.01043) [pdf, other]

**[Are clinicians ethically obligated to disclose their use of medical machine learning systems to patients?](#)**

Joshua Hatherley

Comments: 21 pages. Journal of Medical Ethics, forthcoming 2024

**Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 05 Apr 2025]

[No new digest content identified]

**medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 05 Apr 2025]

[Filter: All articles]

**[Mapping One Health studies and practices that integrate the human, animal and environmental health dimensions: A scoping review protocol](#)**

Jessica FD Medeiros, Jorge Otávio Maia Barreto, Sindy Maciel Silva, Johnathan Portela da Silva Galdino, Christina Pacheco, Eveline Fernandes Nascimento Vale, Juliana Michelotti Fleck, Kary Desiree Mercedes Santos, Karine Suene Mendes Almeida, Mayara Suelirta Costa, Verônica Cortez Ginani, Wildo Navegantes Araújo, Leonor MP Santos

medRxiv 2025.04.02.25325158; doi: <https://doi.org/10.1101/2025.04.02.25325158>

The growing interconnection between human, animal, and environmental health has escalated the need for integrated approaches to public health. The One Health framework addresses this necessity by promoting local, national, and global interdisciplinary collaboration. Population growth, intensive animal farming, and manmade environmental changes contribute to the emergence and spread of infectious diseases of probable animal origin, such as COVID-19. Establishing the Quadripartite collaboration with four multilateral United Nations' agencies underscores the increasing recognition of these interdependencies. This scoping review protocol aims to evaluate how One Health studies integrate human, animal, and environmental health, analyzing methodologies, scope, and interdisciplinary collaboration, to identify key achievements, existing gaps, and future research priorities. The projected literature search will include PubMed, Web of Science, Scopus, Virtual Health Library, Health Systems Evidence, and Social Systems Evidence. Additionally, grey literature will be retrieved from Opengrey, Thesis Commons, and Open Access Theses and Dissertations, by structured electronic search, as well as the first 100 entries in Google Scholar, manually. This protocol proposes to include studies, policies, regulations, strategies, and interventions published from 2004 onwards aimed at the prevention and integrated management of food safety, zoonotic diseases, antimicrobial resistance, and the impacts of climate change on health...

**[Age-specific immunity to rotavirus infection and the risk of disease before and after rotavirus vaccine introduction in the United Kingdom: an observational, seroepidemiological study](#)**

Daniel Hungerford, Virginia E Pitzer, Khuzwayo C Jere, Marc Y.R Henrion, Jonathan Mandolo, Catherine Beavis, Karen Ryan, Jenna Lowe, Nigel A Cunliffe, Neil French, Miren Iturriza-Gomara  
medRxiv 2025.04.03.25324959; doi: <https://doi.org/10.1101/2025.04.03.25324959>

**[Effectiveness of the Influenza Vaccine During the 2024-2025 Respiratory Viral Season](#)**

Nabin K. Shrestha, Patrick C. Burke, Amy S. Nowacki, Steven M. Gordon  
medRxiv 2025.01.30.25321421; doi: <https://doi.org/10.1101/2025.01.30.25321421> Revision

**[Acceptability and perceived barriers to adoption of the core outcome set for maternal and neonatal health research and surveillance during emerging and ongoing epidemic threats \(MNH-EPI-COS\). An online survey](#)**

Karen Klein, Juan Pedro Alonso, Mabel Berrueta, Olufemi T. Oladapo, Mercedes Bonet, María Belizán, Verónica Pingray  
medRxiv 2025.03.31.25324937; doi: <https://doi.org/10.1101/2025.03.31.25324937>

**[Effectiveness of COVID-19 vaccine booster doses in adults aged 50 years and over during the Omicron period in Victoria, Australia](#)**

Joshua Szanyi, Yue Yang, Jiaxu Zeng, Chris Clarke, Amanda K Buttery, Tony Blakely  
medRxiv 2025.03.31.25324986; doi: <https://doi.org/10.1101/2025.03.31.25324986>

**[Accounting for cross-registration in monitoring responsible research in clinical trials: A cross-sectional study of trials at German university medical centers](#)**

Luciano Fernandez, Elisa Bascunan Atria, Samruddhi Yerunkar, Maia Salholz-Hillel, Vladislav Nachev, Susanne Gabriele Schorr, Daniel Strech, Delwen L. Franzen  
medRxiv 2025.04.01.25325043; doi: <https://doi.org/10.1101/2025.04.01.25325043>

Identifying and monitoring clinical trials is crucial for responsible research systems and is relevant to all stakeholders in clinical research. Trial registries support accountability and transparency by providing a publicly available and rich source of information on trials. Cross-registration, where the same trial is registered in more than one registry, can complicate efforts to study the clinical research enterprise. Duplicate entries may need to be de-duplicated or merged, and discrepancies across registrations may affect conclusions about trial adherence to registration and reporting standards...

**[Assessing MMR Vaccination Strategies in Texas: A Scenario-Based Modeling Study of Measles Outbreaks](#)**

Kaiming Bi, Thuy Nguyen, Boya Peng, Trudy Krause, Cecilia Ganduglia Cazaban, Janelle Rios, Cici Bauer, Catherine Troisi, Eric Boerwinkle, Aanand D. Naik  
medRxiv 2025.03.25.25324613; doi: <https://doi.org/10.1101/2025.03.25.25324613> Revision

**[The Pandemic's Echo: A Population-Based Assessment of MMR Rates and Associated Factors in the Wake of COVID-19](#)**

Ensheng Dong, Samee Saiyed, Andreas Nearchou, Yamato Okura, Lauren M. Gardner  
medRxiv 2025.02.13.25322239; doi: <https://doi.org/10.1101/2025.02.13.25322239> Revision

**[The development and usability testing of six arts-based knowledge translation tools for parents about COVID-19](#)**

Shannon D. Scott, Sarah A. Elliott, Kathy Reid, Lisa Knisley, Lisa Hartling  
medRxiv 2025.03.31.25324968; doi: <https://doi.org/10.1101/2025.03.31.25324968>

**OSF Pre-prints**

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>  
[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre-prints]  
**[Website not responding at inquiry]**

**Wellcome Open Research**

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 05 Apr 2025]  
[No new digest content identified]

\* \* \* \*

### **Think Tanks**

**Brookings** [to 05 Apr 2025]  
<http://www.brookings.edu/>  
*Reports, Events*  
*No new digest content identified.*

**Center for Global Development** [to 05 Apr 2025]  
<https://www.cgdev.org/>  
*All Research*  
*No new digest content identified.*

**Chatham House** [to 05 Apr 2025]  
<https://www.chathamhouse.org/>  
*Selected Analysis, Comment, Events*  
*No new digest content identified.*

**Council on Foreign Relations** [to 05 Apr 2025]  
<https://www.cfr.org/media/news-releases>  
*New Releases [Selected]*  
*No new digest content identified.*

**CSIS** [to 05 Apr 2025]  
<https://www.csis.org/>  
*Reports [Selected]*  
*No new digest content identified.*

**Kaiser Family Foundation** [to 05 Apr 2025]  
[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)  
*Newsroom*  
*No new digest content identified.*

**McKinsey Global Institute** [to 05 Apr 2025]  
<https://www.mckinsey.com/mgi/overview>  
*Latest Research*  
*No new digest content identified.*

**ODI [Overseas Development Institute]** [to 05 Apr 2025]  
<https://odi.org/en/publications/>

*Publications [Selected]*  
*No new digest content identified.*

**Pew Research Center** [to 05 Apr 2025]  
<https://www.pewresearch.org/>  
*Latest Publications [Selected]*  
*No new digest content identified.*

**Rand** [to 05 Apr 2025]  
<https://www.rand.org/pubs.html>  
*Published Research [Selected]*  
*No new digest content identified.*

**Urban Institute** [to 05 Apr 2025]  
<https://www.urban.org/publications>  
[\*\*New Research Publications - Selected\*\*](#)

**World Economic Forum** [to 05 Apr 2025]  
<https://agenda.weforum.org/press/>  
*Media [Selected]*  
*No new digest content identified.*

\* \* \* \*

***Contents [click to move among sections]***  
*:: [Milestones, Perspectives](#)*  
*:: [WHO](#)*  
*:: [Organization Announcements](#)*  
*:: [Journal Watch](#)*  
*:: [Pre-Print Servers](#)*

\* \* \* \*  
\* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy ([CVEP](#)) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2025. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the [Bill & Melinda Gates Medical Research Institute](#), and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

*	*	*	*
*	*	*	*